Canephron is a herbal antimicrobial agent

Medicine Canephron

Thanks to the properties of the herbal components that make up the drug, Canephron in terms of effectiveness and safety is in many ways superior to analogues from the same series of drugs for problems with the health of the kidneys and genitourinary system. The active components of the drug stop inflammatory processes and have an antimicrobial effect at the same time.

Composition of Canephron

The composition of the drug is dominated by herbal components, which are supplemented and enhanced by excipients:

• centaury grass,
• lovage root
• common rosemary leaves,

Lactose monohydrate, corn starch, silicon dioxide, magnesium stearate, povidone K 25 are used as additional ingredients that enhance the effect of plant components.

Release form and dosage

The drug is produced in two versions - solution and tablets.

Taking the solution

The drug does not have a very pleasant taste, so it is recommended to either dilute the dose in water or simply drink it with a large amount of warm liquid.

Inside, diluted in a small amount of water or washed down with water. Adults: 50 drops 3 times a day. School-age children: 25 drops 3 times a day. For preschool children (over 1 year): 15 drops 3 times a day. After the severity of the disease has subsided, treatment with the drug should be continued for 2-4 weeks.

If necessary, for example, to soften the bitter taste for children, the drug can be taken with other liquids. During treatment with the drug, it is recommended to consume plenty of fluids. Shake before use!

Canephron H

The German pharmaceutical company is a recognized leader in the production of herbal medicines. One of her most successful creations is the combined herbal medicine Canephron, which literally contains a whole “botanical garden” of healing plant ingredients. Thus, centaury herb has a diuretic and antimicrobial effect, lovage root has an antispasmodic effect, and rosemary leaves have an anti-inflammatory effect.

In the “dry” residue, canephron has a pronounced antimicrobial, antispasmodic and anti-inflammatory effect on the urinary tract, stimulates blood circulation and reduces the permeability of the walls of the renal capillaries, has a diuretic effect, increases the efficiency of the kidneys, and enhances the effect of complex antimicrobial therapy. One of the main pharmacological “trump cards” of the drug is water diuresis. An increase in urination occurs due to the dilation of blood vessels in the kidneys caused by lovage essential oils and the intensification of blood circulation in this area. The bitterness of centaury also helps the vessels expand. The diuretic effect of canephron is due to phenolcarboxylic acids, which are contained in abundance in the plant components of the drug. They, along with lovage phthalides, have an antispasmodic effect. Rosmarinic acid has an anti-inflammatory effect. All components of canephron have an antimicrobial effect, because they contain substances with appropriate pharmacological activity (secoiridoids, phenolcarboxylic acids and others).

Canephron is rarely used in “solo” mode: given its ability to increase the effectiveness of antibiotic treatment, it is most often used as part of complex treatment. The drug is well tolerated and has proven itself only from the best side in terms of safety. However, you should clearly understand that no matter how wonderful properties medicinal herbs have, a clear effect from their use can only be noticed with long-term use. If the course of the disease is aggravated by an actively developing inflammatory process and persistent elevated body temperature, then one cannot rely only on plant canephron.

The drug is available in the form of an oral solution and tablets. The solution can be washed down with water, or diluted with a small amount of liquid. Adults, as a rule, are prescribed 50 drops three times a day, schoolchildren - half as much with the same frequency of administration, and preschool children - 15 drops 3 times a day. Before use, the bottle with the solution must be shaken several times. For pills, the recommended dosages are as follows: 2 pcs. 3 times a day for adults and 1 pc. 3 times a day for school-age children. The weakening of symptoms does not indicate the need to stop taking Canephron: it should be continued for another 2-4 weeks, accompanying herbal medicine with the consumption of large amounts of fluid.

Taking pills

Adult patients are prescribed 2 tablets three times a day. Children over 6 years old are prescribed 1 tablet also three times a day.

It is not necessary to chew the tablets. They are covered with a smooth shell, which makes them easy to swallow. After the acute period of the disease has passed, treatment is continued for another two to four weeks.

The drug is continued after the acute period of the disease has passed. It usually takes two to four weeks. The exact date is determined by the doctor.

Canephron treatment regimens

The standard period during which Canephron is taken is 21 days. It is during this period of time that the remedy not only manages to destroy pathogenic bacteria, but also prevents their reappearance and a new outbreak of exacerbation.

The exact course of treatment is prescribed by the doctor depending on the established diagnosis and indications. Before taking Canephron, you must undergo all tests and collect anamnesis. For example, when treating cystitis and pyelonephritis, a longer course may be required. In addition, complex treatment is often required in conjunction with other drugs, including the use of antibiotics.

Canephron N reviews

Canephron N is a herbal medicine that has existed on the pharmaceutical market for more than 80 years. It was created pharmaceutically in 1934 in Germany and is still produced today.

Canephron N can be called one of the herbal remedies studied. Since 1973, the effectiveness and safety of Canephron N in the treatment and prevention of urological diseases, including in pregnant women, has been actively studied in Russia, Belarus, Ukraine, and Kazakhstan. During this time, more than 20 large multicenter studies have been conducted, some of which are randomized. The research results are published in medical periodicals (Breast Cancer Journal, “Attending Physician” journal, “Obstetrics and Gynecology” journal, “Obstetrics and Women’s Diseases” journal, “Bulletin of Modern Clinical Medicine”, etc.), as well as at numerous scientific and practical conferences dedicated to women's and reproductive health.

According to the results of ongoing studies, Canephron N has proven its effectiveness and safety for the treatment of various urological pathologies in pregnant women (in the treatment of glomerular diseases, pyelonephritis, urolithiasis, asymptomatic bacteriuria, edema of pregnant women, microalbuminuria of any origin). Canephron N has been used both in monotherapy and in combination with various antibacterial drugs. Studies have shown that when using Canephron N, it is possible to shorten the duration of therapy, lengthen the time of remission, and reduce the incidence of moderate and severe diseases. The drug was well tolerated and there were no side effects.

The main factor that allows the use of Canephron N in pregnant women is the absence of any negative effects on the fetus. Canephron N does not have mutagenic effects, does not have embryo- or fetotoxic effects.

However, despite the results of numerous studies, the herbal medicine Canephron N is not included in the standards and clinical recommendations for the treatment and prevention of urological diseases in pregnant women.

In my practice, I use Canephron N as monotherapy - only for the prevention of urological diseases in pregnant women with a complicated medical history of this profile. When treating urological diseases, I use Canephron N only in combination with antibacterial drugs. In my practice, I also did not notice the development of side effects or intolerance to Canephron N.

However, if urological diseases develop, I do not recommend self-medication. Only your attending physician can prescribe an adequate treatment regimen.

Doctor's assessment:

2017-10-06 12:51:46

Indications

Canephron is prescribed as an independent medicine or as one of the components of complex treatment:

• for acute diseases of the kidneys and urinary tract, and also for the chronic course of the disease and as a preventive therapy;
• as an auxiliary component in the treatment of urolithiasis, as well as after stone removal.
• For cystitis, Canephron is taken as an antibacterial agent. During the process of disease in the human genitourinary system, bacteria actively and quickly multiply and enter the bladder through the urethra. This is what provokes acute pain attacks and frequent urge to urinate. Canephron helps destroy bacteria.
• In the treatment of pyelonephritis, the drug plays an auxiliary role and is prescribed in combination with other drugs.
• When diagnosing a sexually transmitted infection, urethritis, antibacterial treatment is also necessary. Canephron is prescribed in combination with antibiotics. Thanks to this combination, the effect of additional disinfection is achieved, and the increased diuretic effect allows you to quickly cope with the infection. In addition, the herbal components that make up Canephron have a calming effect, reducing pain.
• In the treatment of urolithiasis, Canferon is also used in combination with other drugs. During the course of the disease, the patient experiences severe acute pain, which is provoked by sand and kidney stones. Canephron helps relieve renal colic and promotes faster removal of sand from the patient’s body.
• The drug is prescribed as an antibacterial agent for prostatitis.

In addition, Canephron is used as a prophylactic agent, as well as in the treatment of inflammation of the external genitalia, disorders of the gastrointestinal tract and other infectious diseases accompanied by acute pain.

Effects and indications of the drug

Canephron, the instructions emphasize this, has a mild diuretic effect. A unique combination of plant oils reduces inflammation and relieves spasms of the urinary tract. When taking the drug, the effectiveness of antibiotics increases. Thanks to the essential oils in the composition, it is possible to stabilize the process of urination and reduce the likelihood of exacerbation of chronic cystitis. Canephron, the instructions for use confirm this, promotes the excretion of urates, which ensures the prevention of urolithiasis.

It is important to know what Canephron helps with in order to make the right decisions about treatment with the drug. The drug is most often prescribed for the treatment of cystitis. It reduces severe pain in the bladder area and reduces pain when urinating. The product is well compatible with antibiotics, which allows for successful treatment of cystitis in a short time.

Canephron tablets, the instructions for use emphasize this, are prescribed for the maintenance treatment of chronic inflammation of the urinary tract. Thanks to the use of the drug, it is possible to reduce the risks of exacerbations and relapses.

Canephron N is prescribed, the instructions for use reflect this, both as an independent remedy and as a component in complex therapy. In addition to the treatment of kidney and urinary tract diseases in the acute stage, the drug is considered effective for the following pathologies:

• Cystitis.
• Pyelonephritis
• Urolithiasis
• Urethritis.
• Prostate.

Contraindications

Despite the almost one hundred percent content of herbal components that make up the drug, Canephron is contraindicated in the following cases:

• children under 6 years of age;
• the drug has a choleretic effect, so it is not recommended for patients with an acute condition of gastric and duodenal ulcers;
• with lactose and fructose intolerance, deficiency of lactase, sucrase, isomaltase and glycoso-galactose malabsorption;
• with sensitivity or intolerance to individual components of Canephron.

The Canephron solution contains about 20% ethanol. In this regard, Canephron is used with great caution in patients who previously or at the time of treatment had problems with alcohol consumption.

During pregnancy and breastfeeding, Canephron should be taken only after consultation with a doctor. All necessary tests are collected in advance. If the drug was nevertheless prescribed by a doctor, it is necessary to strictly adhere to the dosage and regimen of the drug.

Side effects

While taking the drug, some side effects may occur. Sometimes an allergic reaction to some of the components of the product occurs. In this case, stop using the drug immediately. Gastrointestinal disturbances accompanied by nausea, vomiting and diarrhea are possible.

Compatibility of Canephron with other drugs

Canephron has no contraindications for combination with other drugs from the category of antibiotics, diuretics, analgesics and non-steroidal anti-inflammatory drugs. Complex use is possible only after consultation with a doctor who will prescribe clear dosages of Canephron and other medications. Independent attempts to take the drug with other medications can lead to side effects and reduce the effectiveness of the overall treatment, both of each drug separately and in combination.

Canephron is one of the most effective drugs today in the fight against diseases of the genitourinary system and kidneys in both women and men. Thanks to its composition of plant origin, Canephron is much superior to existing analogues. The drug very rarely causes allergic reactions, due to which it is widely used. In addition, the drug helps reduce protein, which is excreted in the urine during treatment and is more effective than similar medications.

The use of Canephron N for urolithiasis

The past three decades have been marked by significant strides in the diagnosis and treatment of urolithiasis. Numerous risk factors for this disease have been identified and studied. High-tech, highly effective and at the same time minimally invasive methods of stone disintegration have been introduced into clinical practice. With the advent of multislice computed tomography (MSCT), determining the number and location of stones is not difficult, regardless of their chemical and phase composition [1,2]. However, the flow of patients suffering from urolithiasis is not decreasing. The reason for this seemingly paradoxical phenomenon is quite simple - the lack of continuity between inpatient and outpatient urological services, as well as clear and effective recommendations for the prevention of recurrent stone formation [4]. ICD is widespread, and in many countries around the world there is a trend towards an increase in incidence. Most likely, this is due to changes in diet, sedentary lifestyle, and exposure to a variety of unfavorable environmental factors. In terms of occurrence among urological diseases, nephrolithiasis ranks second after urinary tract infections. ICD is detected at any age, most often in working age (20–55 years), but can also occur in children. Despite the large variation in the identified components of urinary stones, according to the chemical composition they are all combined into three main groups: • urate stones (stones consisting of uric acid salts); • calcium oxalate stones; • phosphate stones. Stones in urolithiasis can be localized in all parts of the urinary system: in the calyces and pelvis of the kidneys, ureters, bladder and urethra. More often the disease is unilateral, but stones may appear on both sides. Stones in the kidneys or urinary tract can be single or multiple. The size of the stones can also vary from 1 mm to several centimeters. In approximately 30% of patients, stones form again, and the disease becomes recurrent. At present, the cause of the formation of stones has not been fully established. ICD can develop due to hereditary predisposition. However, additional factors play an important role - climatic and geographical conditions of a person’s place of residence, dietary habits, some diseases of the gastrointestinal tract and genitourinary system. The development of KSD can be facilitated by a complex of external and internal reasons: • external reasons: dietary habits, physical and chemical properties of water, harmful working conditions, sedentary lifestyle, lack of vitamins A and B in food, the use of certain medications (sulfonamides, excessive consumption of ascorbic acid – vitamin C); • internal causes: abnormal development of the kidneys and urinary tract, urinary tract infections; deficiency of any of the enzymes, leading to disruption of normal metabolism, diseases of the gastrointestinal tract, prolonged state of immobility (immobilization for fractures). Pain is the most common manifestation of urolithiasis. It can be constant or intermittent, dull or acute. The localization and radiation of pain depend on the location and size of the stone. Large pelvic stones and coral kidney stones are inactive and cause dull pain, often constant, in the lumbar region. ICD is characterized by a connection between pain and movement, bumpy driving, and heavy physical activity. For small stones, attacks of renal colic are most typical, which is associated with their migration and a sharp disruption of the outflow of urine from the calyces and/or pelvis. Pain from the lumbar region often radiates along the ureter to the iliac region. As the stone moves into the lower third of the ureter, the irradiation of pain changes: it begins to spread lower, into the groin area, into the testicle, glans penis in men and labia in women. There is a sharp urge to urinate and frequent urination. Renal colic caused by a stone occurs suddenly after driving, shaking, drinking plenty of fluids, drinking alcohol, but sometimes even against the background of complete well-being. Patients constantly change position, often moan and even scream. This characteristic behavior of the patient often makes it possible to establish a diagnosis “at a distance.” The pain sometimes continues for several hours or even days, periodically subsiding. The cause of renal colic is the sudden cessation of urine flow from the calyces and/or pelvis caused by occlusion of the upper urinary tract by a stone. Violation of the outflow of urine leads to overflow and overstretching of the calyces and/or pelvis with urine, an increase in intrapelvic pressure, which, in turn, causes irritation of the receptors of the sensory nerves of the hilum and the fibrous capsule of the kidney. Pain occurs and increases due to impaired microcirculation in the kidney and developing hypoxia of the renal tissue and the nerve endings of the plexuses innervating the kidney. Quite often, an attack of renal colic can be accompanied by chills, increased body temperature, and leukocytosis, which is caused by pyelovenous and pyelotubular reflux. Often, simultaneously with renal colic, patients experience nausea, vomiting, flatulence, muscle tension in the abdominal wall, and reflex intestinal paresis, simulating the picture of an acute abdomen. Stone passage can be considered a pathognomonic sign of ICD. As a rule, small stones (up to 0.5–0.6 cm) are capable of spontaneous passage, however, with a decrease in the tone and urodynamics of the upper urinary tract (developmental anomalies, strictures, deviations, etc.), stone passage is difficult or becomes impossible. In the diagnosis of KSD, laboratory and imaging methods are used. Laboratory examination methods include: • clinical blood test; • biochemical blood test (determination of the level of potassium, calcium, creatinine, urea, uric acid, sodium, inorganic phosphorus in the blood serum); • general urine analysis; • biochemical urine analysis (determination of the level of potassium, calcium, uric acid, sodium, oxalates); • pH-metry of urine in the morning, afternoon and evening with the patient’s usual regimen and diet for several days (with litholysis planned in the future); • bacteriological examination of urine; • Rehberg's test; • analysis of the composition of urinary stones. All stones that pass spontaneously or are removed in one way or another must be subjected to chemical analysis, which will complement the data on the nature of metabolic disorders and will allow us to develop adequate tactics of drug therapy in order to prevent relapse of stone formation. Of the instrumental methods of examination, the following are necessary: ​​• Ultrasound of the kidneys (the location of the stone, its size, the thickness of the kidney parenchyma, the condition of the pyelocaliceal system are assessed); • plain radiography of the urinary system; • excretory urography; • radioisotope study of kidney function; • CT scan. If a laboratory examination reveals the following triad - hypercalcemia, hypophosphatemia and hypercalciuria - the patient is indicated for an endocrinological examination to exclude hyperparathyroidism. In case of bilateral urolithiasis or rapidly recurrent stone formation (within several months) in the absence of the above complex of metabolic disorders, the patient is also indicated for an endocrinological examination to determine the condition of the parathyroid glands. If renal tubular acidosis is suspected, an ammonium chloride test is performed. Getting rid of the stone is the main stage of treatment for a patient suffering from urolithiasis. The emergence in recent years of new, high-tech methods for the treatment of urolithiasis, such as external shock wave lithotripsy (ESWL), percutaneous and contact lithotripsy, can significantly reduce the size of the stone, but the remaining small fragments of the stone must “pass away” on their own. In this regard, the role of lithokinetic therapy is increasing, designed to ensure the evacuation of small stones from the kidneys and upper urinary tract. In addition, stone removal only creates conditions for improving urodynamics and treating the inflammatory process in the urinary tract, but does not affect the metabolic processes occurring in the patient’s body. Therefore, the need for dynamic postoperative metaphylaxis of urolithiasis relapse becomes obvious, which ultimately determines the effectiveness of treatment. The result of any surgical intervention can be nullified if, after discharge from the hospital, treatment and monitoring of the patient does not continue for a long time [4]. The herbal preparation Canephron®N (Bionorica, Germany) has proven itself well as a component of lithokinetic therapy and a means of metaphylaxis. Canephron®N is a combination drug that contains centaury (Centaurium umbellatum), lovage (Levisticum officinale) and rosemary (Rosmarinus officinale). The substances included in the drug have an antiseptic, antispasmodic, anti-inflammatory effect on the organs of the urinary system, reduce the permeability of the capillaries of the kidneys, have a diuretic effect, improve kidney function, and potentiate the effect of antibacterial therapy. Various types of action of Canephron®N are due to its constituent essential oils, phenolcarbolic acids, phthalides, and bitters. The advantage of the drug is the combination of anti-inflammatory and antimicrobial effects, which is especially valuable in the presence of chronic inflammatory processes in the urinary tract, which mostly accompany the course of urolithiasis. The excretion of organic phenolcarboxylic acids and their glucuronidated and sulfated metabolites in urine leads to changes in urine pH, which counteracts bacterial growth. In addition, Canephron®N enhances the excretion of uric acid salts, and this effect is only partly related to the diuretic effect and is quite specific. Increasing the excretion of uric acid prevents the loss of crystals in the urinary tract and the growth of existing stones and the formation of new stones. Changing urine pH to 6.2–6.8 also prevents urate stone formation. It is well known that a necessary condition for maintaining salts in dissolved form is the concentration of hydrogen ions, an indicator of which is urine pH. A normal pH value of 6.2–6.4 ensures a stable colloidal state of urine. According to many authors, among the causes of impaired renal function, an important role is played by congenital or acquired enzymopathies, in which the distal and proximal tubules are damaged (tubulopathies), congenital malformations of the anatomical development of the urinary tract, leading to the formation and excretion of defective urine and playing an important role. role in stone formation. The most common tubulopathies that contribute to stone formation are oxaluria, uraturia, cystinuria, aminoaciduria, galactosemia, fructosemia. The effect of Canephron®N on the tubular apparatus of the kidney has been pharmacologically proven. The studies carried out clearly show that the excretion of protein in the urine, due to previously suffered pathological processes that damage the tubular apparatus, is sharply reduced. The above complex of pharmacological effects determines the widespread use of the drug Canephron®N in urological practice. At the Urological Clinic of the MMA named after I.M. Sechenov has experience in using Canephron®N after ESWL to accelerate the passage of disintegrated stone fragments, as well as to prevent relapses of urolithiasis [3,5–7]. 79 patients with urolithiasis were examined: 45 of them were included in the Canephron®N group (main group) and 34 in the control group. The Canephron®N group consisted of 45 patients (27 men and 18 women) aged from 29 to 55 years. The duration of the disease in most patients averaged 3–5 years. During the examination, kidney or ureteral stones were detected in all patients (Table 1). The control group consisted of 34 patients (19 men and 15 women) aged from 34 to 62 years. The duration of the disease in most patients averaged 2–4 years. During the examination, kidney or ureteral stones were detected in all patients (Table 2). When examining patients in both the main and control groups, attention was paid to leukocyturia, urine pH value, and daily diuresis. In the main group, leukocyturia was detected in 29 (64.4%) patients, in the control group - in 15 (44.1%) patients. The urine pH value in the main and control groups averaged 5.7, daily diuresis was 1300 ml. All patients underwent external shock wave lithotripsy. Patients of the main group were prescribed Canephron®N as part of drug therapy, 2 tablets 3 times a day. Patients in the control group received antispasmodic and anti-inflammatory therapy without the prescription of Canephron®N. The criteria for assessing the effectiveness of the drug Canephron®N were the timing of passage of disintegrated stones after extracorporeal shock wave lithotripsy, a decrease in leukocyturia, an increase in daily diuresis, and normalization of urine pH. Disintegration of disintegrated stones within the first 5 days. after external shock wave lithotripsy in group A (n=22) occurred in 16 (72.7%) patients, while in group A1 (n=12) - in 4 (33.3%) patients. 2 patients from group A and 3 patients from group A1 required a repeat session of external shock wave lithotripsy. Disintegration of disintegrated stones within the first 5 days. after external shock wave lithotripsy in group B (n=7) occurred in 5 (71.4%) patients, while in group B1 (n=8) - in 3 (37.5%) patients. 1 patient from group B1 required a repeat session of external shock wave lithotripsy. Disintegration of disintegrated stones within the first 5 days. after external shock wave lithotripsy in group C (n=6) occurred in 4 (66.6%) patients, while in group C1 (n=5) - in 2 (40%) patients. Disintegration of disintegrated stones within the first 5 days. after external shock wave lithotripsy in group D (n=10) occurred in 9 (90%) patients, while in group D1 (n=9) - in 5 (55.5%) patients. Thus, it is obvious that the use of Canephron®N as part of complex therapy after external shock wave lithotripsy accelerates the passage of stone fragments from the urinary tract, regardless of the level of their initial localization. Apparently, this is due to the complex antispasmodic and diuretic effect of the drug, as well as its antimicrobial and anti-inflammatory effect, as a result of which inflammatory changes in the mucous membrane of the urinary tract decreased. This hypothesis is confirmed by the fact that the disappearance of leukocyturia on the 7th day. in the main group it was observed in 27 (93.1%) patients, while in the control group - in only 7 (46.6%) patients. In the Canephron®N group, no increase in the number of leukocytes was observed in control urine tests; Urine pH was maintained in the range of 6.2–6.8; daily diuresis increased to 2–2.5 l. Not a single patient showed signs of intolerance, side effects or complications when taking the drug Canephron®N. Thus, the analysis of the study allows us to consider the drug Canephron®N as an effective and safe drug for the treatment of patients with urolithiasis, including patients who have undergone external shock wave lithotripsy. The study of the effectiveness of Canephron®N for the prevention of recurrent stone formation included two groups - the main (35 patients - 20 men and 15 women) and the control (25 patients - 15 men and 10 women) aged from 31 to 68 years after minimally invasive surgical interventions [4]. In each group, four subgroups were formed into which patients with various changes in biochemical blood tests and 24-hour urine tests were divided. The distribution of patients into subgroups is presented in Table 3. All patients received special (drug) metaphylaxis for ICD, depending on the identified metabolic changes. Patients in the main group additionally took Canephron®N 2 tablets (50 drops) x 3 times a day. at least 3 months During the therapy, a decrease in the level of calcium and uric acid in the urine was revealed, the pH of the urine was stabilized at the level of 6.2–6.8, in addition, a decrease in the doses of medications used was noted, and the pH was stabilized at the required level. The results of control blood and urine tests are presented in Table 4. With continued use of Canephron®N for up to 6 months. in all groups, the pH and concentration of stone-forming substances in the urine remained within normal values. The use of Canephron®N has great promise in the complex dynamic metaphylaxis of KSD. The drug not only increases the effectiveness of primary drug therapy, but also helps achieve longer remission of the disease.

Literature 1. Alyaev Yu.G., Amosov A.V., Gazimiev M.A.. Ultrasound methods of functional diagnostics in urological practice. M: “R. Valens”. 2001 2. Alyaev Yu.G., Rapoport L.M., Rudenko V.I., Grigoriev N.A. Urolithiasis disease. Current issues of diagnosis and treatment. 3. Amosov A.V. Herbal preparation Canephron in urological practice. Doctor, No. 6, 2000, p. 36. 4. Amosov A.V., Alyaev Yu.G., Saenko V.S. Herbal preparation Canephron N in postoperative metaphylaxis of urolithiasis 5. Kalinina S.N., Aleksandrov V.P., Tiktinsky O.L., Korenkov D.G. Canephron in the treatment of patients with urolithiasis after surgery. Materials of scientific works of the VII International Congress of Urologists, Ukraine, Kharkov, 1999, p. 213–214. 6. Kalinina S.N., Tiktinsky O.L., Aleksandrov V.P. et al. Treatment of patients with urolithiasis (KD) with Canephron N in combination with Wobenzym during DLT // Plenum of the Board of the Russian Society of Urologists: Materials, Sochi, April 28–30, 2003 - M.: 2003, p. 156–157. 7. Pytel Yu.A., Amosov A.V. Herbal preparation Canephron in urological practice. Attending physician, No. 6, 1999, p. 38–39.